Treatment concept successfully translated into human patients-Reference-Cited by-同舟云学术

Treatment concept successfully translated into human patients

Published:2023-02-28 Issue: Volume: Page:48-51
ISSN:
Container-title:Exploration of Neuroscience
language:en
Short-container-title:Explor Neurosci

Author:

Hermann Dirk M.¹^ORCID

Affiliation:

1. Department of Neurology, University Hospital Essen, University of Duisburg-Essen, D-45122 Essen, Germany

Publisher

Open Exploration Publishing

Subject

General Agricultural and Biological Sciences,Philosophy,Classics,Physical and Theoretical Chemistry,Mechanical Engineering,General Chemical Engineering,Infectious Diseases,Cell Biology,Cellular and Molecular Neuroscience,Biochemistry,Law,Social Sciences (miscellaneous),History,General Economics, Econometrics and Finance,Business and International Management,Mechanical Engineering,Ocean Engineering,Aerospace Engineering,Condensed Matter Physics,Nuclear Energy and Engineering,Civil and Structural Engineering,Statistical and Nonlinear Physics,Statistics and Probability,Industrial and Manufacturing Engineering,Management Science and Operations Research,Statistics, Probability and Uncertainty,Statistics and Probability

Reference8 articles.

1. Hermann DM. Cutting edges in neuroscience to exceed borders. Explor Neurosci. 2022;1:1–3.

2. Jellinger KA. Recent developments and future perspectives of neuropathology. Explor Neurosci. 2022;1:54–60.

3. Lecanemab confirmatory phase 3 Clarity AD study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheimer’s disease [Internet]. Biogen; c2023 [cited 2022 Nov 11]. Available from: https://investors.biogen.com/news-releases/news-release-details/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary

4. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21.

5. Aducanumab (marketed as Aduhelm) information [Internet]. [cited 2022 Nov 11]. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information